ArticleSpinal cord2026
Intramedullary injection of polymerized laminin in acute traumatic spinal cord injury: a first-in-human pilot study.
Article in Spinal cord, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
STUDY
designInvestigator-initiated, single-arm, first-in-human pilot study.
objectivesTo evaluate the safety and feasibility of intramedullary administration of polymerized laminin in individuals with acute complete spinal cord injury (SCI).
settingPublic and private hospitals in Brazil.
methodsEight patients with acute traumatic SCI classified as AIS A (C4-T12) were enrolled within days after injury (mean 2.3 days). Polymerized laminin was administered as a single intramedullary dose (1 µg/kg; total 55-80 µg). Patients were followed for 12 months using standardized neurological, laboratory, and neurophysiological assessments.
resultsIntramedullary administration was uneventful in all cases. No neurological deterioration or serious adverse events attributable to the intervention were observed. Mild laboratory abnormalities were transient and not associated with hepatic or renal toxicity. Three participants died during follow-up. Deaths were reviewed by the Brazilian National Research Ethics Commission (CONEP) and an external clinical consultant, and were not considered related to the intervention. Neurological improvement of at least two AIS grades was observed in six participants, including one who died after progressing to AIS C. Improvements in motor and/or somatosensory evoked potentials were observed in three patients.
conclusionsIntramedullary administration of polymerized laminin was uneventful and appeared to be safe in this small and heterogeneous cohort. Although the study design does not allow conclusions regarding efficacy, it provides proof-of-concept for this therapeutic approach and justifies further evaluation in controlled clinical studies. The study was initiated in December 2016, prior to current requirements for prospective trial registration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.